I recently pinned an article outlining why Allergan (NYSE:AGN) would be a fantastic addition to your portfolio in 2017. Titled “Icahn Sells Allergan: A Rebuttal”, we determined that Carl Icahn has a net zero effect on the company. More importantly though, we determined that Allergan’s shares are inexpensive and their products are strong and growing.
Allergan’s shares have roared to the upside since the first week of December last year. They’ve taken off like a rocket for nearly a 20% gain in less than a month.
Why? Well, the shares were absurdly....More>>>